An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the objective response rate (complete response [CR]+
partial response [PR]) of the selected dose regimen in participants with metastatic or
surgically unresectable urothelial cancers that harbor specific FGFR genomic alterations.